Ph.D., Founder, TMDx Consulting LLC
Dan has nearly 30 years’ experience in the clinical oncology diagnostics and biomarker space and most recently founded TMDx Consulting LLC focused on the translational aspects of clinical diagnostics development. Prior to TMDx Consulting, Dan built and led the Translational Medicine and Diagnostics group at Morphotek, Inc, responsible for the discovery and translation of diagnostics into clinical development in oncology. Previous management roles including COO of Targeted Diagnostics & Therapeutics, Inc., Senior Director of Strategic Planning, Oncology Diagnostics at Gen-Probe, Inc., and CSO at Fujirebio Diagnostics, Inc. Prior to his career in industry Dan was a Visiting Fellow at the NIH and a Docent in Biochemistry at the University of Lund, Sweden. Dan has several FDA cleared oncology diagnostics to his credit, nearly 100 peer-reviewed publications and multiple issued and pending patents in the field of diagnostics.
Presentation Title and Company Description
Liquid Biopsy Showcase: Liquid Biopsies – Planes, Trains and Automobiles
ANGLE is a world-leading liquid biopsy company commercializing a disruptive platform technology, Parsortix™ cell separation system. The Parsortix system can capture and harvest rare cells circulating in blood, such as cancer cells, for analysis.